References
- Lammers RJ, Witjes JA. Developments in intravesical therapy for non-muscle-invasive bladder cancer. Expert Rev. Anticancer Ther.10(12), 1903–1916 (2010).
- Valstar™ (valrubicin). Full Prescribing Information, Endo Pharmaceuticals Inc., Chadds Ford, PA, USA (2009).
- Gontero P, Bohle A, Malmstrom PU et al. The role of bacillus Calmette–Guerin in the treatment of non-muscle-invasive bladder cancer. Eur. Urol.57(3), 410–429 (2010).
- Filion MC, Lepicier P, Morales A, Phillips NC. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br. J. Cancer79(2), 229–235 (1999).
- Morales A. Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent. Expert Opin. Investig. Drugs17(7), 1067–1073 (2008).
- Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J. Urol.181(3), 1040–1045 (2009).
- Morales A, Herr H, Kamat A et al. Phase III study to evaluate the efficacy and safety of mycobacterial cell wall–DNA complex in the treatment of patients with non-muscle invasive bladder cancer at high risk of progression and who are refractory to BCG. Presented at: American Urological Association Annual Meeting. Washington, DC, 14–19 May 2011.
- Morales A, Herr H, Steinberg G et al. Efficacy and safety of mycobacterial cell wall DNA complex in the treatment of patients with non-muscle invasive bladder cancer at high risk of progression and refractory to BCG. Presented at: 26th Annual European Association of Urology Congress. Vienna, Austria, 18–22 March 2011.
Website
- ClinicalTrials.gov http://clinicaltrials.gov